🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 50% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Veggie Capsule(s) Serving Size
60 Servings
Vitamin Product Type
50% Evidence Coverage

Supplement Facts — Evidence Check

Vitashine
125 mcg (625% DV)
100 mcg
✅ Within RDA (0.8× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.1mg

Other Ingredients

Rice Flour Hypromellose Maltodextrin Microcrystalline Cellulose Cornstarch Silica

Label Claims — Verification

Nutrient
All Other
Structure/Function
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Vegan Vegetarian Adult (18 - 50 Years) Women (not pregnant or lactating) Dairy Free

Product Information

📋 Directions for Use

Suggested use: As a dietary supplement, take one veggie capsule per day with food and water.

⚠️ Warnings & Precautions

Warning: For adults only. Keep out of reach of children.

Do not take this product if you have a renal disorder or if you are pregnant or nursing. Consult your healthcare provider before use if you have a medical condition or if you are taking medication, especially blood-thinning medication.

Keep your healthcare provider informed while taking this product to monitor vitamin D blood levels. Do not exceed recommended dose. Do not use if seal is broken.

🧪 Formulation Notes

Contains Vitashine D3

Bone and immune health 2-in-1 formula

Vegan

Additional Information

Store in a cool, dry place.

Product Details

UPC / SKU 0 87614 11804 8
DSLD Entry Date 2024-10-24
Product Type Vitamin
Form Capsule
Brand Swanson
DSLD ID 308815
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →